Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies demonstrating the efficacy of olezarsen in severe hypertriglyceridemia (sHTG). The therapy achieved a placebo-adjusted triglyceride reduction of up to 72% and an 85% decrease in acute pancreatitis events, with a favorable safety and tolerability profile. These findings indicate a substantial therapeutic advancement for sHTG patients, a population of approximately 3 million in the U.S. Ionis is considering label expansions and commercial strategies based on the data.